MX2021001502A - Tratamiento de verrugas. - Google Patents

Tratamiento de verrugas.

Info

Publication number
MX2021001502A
MX2021001502A MX2021001502A MX2021001502A MX2021001502A MX 2021001502 A MX2021001502 A MX 2021001502A MX 2021001502 A MX2021001502 A MX 2021001502A MX 2021001502 A MX2021001502 A MX 2021001502A MX 2021001502 A MX2021001502 A MX 2021001502A
Authority
MX
Mexico
Prior art keywords
warts
treatment
potencies
standardized
compositions
Prior art date
Application number
MX2021001502A
Other languages
English (en)
Inventor
Jr H Stewart Nielsen
Original Assignee
Nielsen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nielsen Biosciences Inc filed Critical Nielsen Biosciences Inc
Publication of MX2021001502A publication Critical patent/MX2021001502A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se describen composiciones que tienen potencias estandarizadas para usar en el tratamiento de verrugas; también se describen métodos para tratar una verruga común que comprenden administrar una o más inyecciones intralesionales de composiciones que tienen potencias estandarizadas a un paciente que lo necesita; además, se describen métodos para tratar una verruga no común que administra una o más inyecciones intralesionales de composiciones que tienen potencias estandarizadas a un paciente que lo necesita.
MX2021001502A 2018-08-06 2019-08-05 Tratamiento de verrugas. MX2021001502A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714942P 2018-08-06 2018-08-06
US201962880742P 2019-07-31 2019-07-31
PCT/US2019/045153 WO2020033329A1 (en) 2018-08-06 2019-08-05 Treatment of warts

Publications (1)

Publication Number Publication Date
MX2021001502A true MX2021001502A (es) 2021-07-15

Family

ID=69228147

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001502A MX2021001502A (es) 2018-08-06 2019-08-05 Tratamiento de verrugas.

Country Status (9)

Country Link
US (3) US11116808B2 (es)
EP (1) EP3833378A4 (es)
JP (1) JP2021535197A (es)
KR (1) KR20210044805A (es)
CN (1) CN112955167A (es)
BR (1) BR112021002156A2 (es)
CA (1) CA3108739A1 (es)
MX (1) MX2021001502A (es)
WO (1) WO2020033329A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614538A (en) * 1994-12-05 1997-03-25 Olin Corporation Synergistic antimicrobial composition containing pyrithione and alcohol
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6350451B1 (en) 1999-06-25 2002-02-26 The Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
CA2276219A1 (en) * 1999-06-25 2000-12-25 Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
US20050175634A1 (en) * 1999-06-25 2005-08-11 The Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
DK1296711T3 (da) 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
CN101914458B (zh) * 2010-02-09 2013-03-13 北京万特尔生物制药有限公司 白假丝酵母(甘露糖蛋白质复合体)菌毛株
WO2011140595A2 (en) 2010-05-10 2011-11-17 4G Vaccines Pty Ltd Immunostimulatory and vaccine compositions
CN104703601A (zh) * 2012-07-03 2015-06-10 格雷斯兰生物科技股份有限公司 用于治疗和抑制病毒感染的组合物和方法
WO2015054678A2 (en) 2013-10-13 2015-04-16 The Board Of Trustees Of The University Of Arkanasas Human papilloma virus therapeutic vaccine

Also Published As

Publication number Publication date
BR112021002156A2 (pt) 2021-05-11
US20200038464A1 (en) 2020-02-06
US11666617B2 (en) 2023-06-06
CN112955167A (zh) 2021-06-11
EP3833378A4 (en) 2022-07-13
US11116808B2 (en) 2021-09-14
WO2020033329A1 (en) 2020-02-13
EP3833378A1 (en) 2021-06-16
US11963991B2 (en) 2024-04-23
US20200376054A9 (en) 2020-12-03
JP2021535197A (ja) 2021-12-16
KR20210044805A (ko) 2021-04-23
US20230256042A1 (en) 2023-08-17
US20210401913A1 (en) 2021-12-30
CA3108739A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201791898A1 (ru) Новые антитела, связывающиеся с tfpi, и содержащая их композиция
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
PH12016502352A1 (en) Pharmaceutical composition
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY193963A (en) Composition for treating joint diseases and kit containing same
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2021001502A (es) Tratamiento de verrugas.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний